Zobrazeno 1 - 10
of 865
pro vyhledávání: '"F. Perini"'
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/b6aa2bdb852a49f1960cda0bac3d6dc3
Publikováno v:
Poultry Science, Vol 100, Iss 2, Pp 441-451 (2021)
The aim of this study was to conduct a genome-wide comparative analysis of 8 local Italian chicken breeds (Ermellinata di Rovigo, Millefiori di Lonigo [PML], Polverara Bianca, Polverara Nera, Padovana, Pepoi [PPP], Robusta Lionata, and Robusta Macula
Externí odkaz:
https://doaj.org/article/b65cd8fb63cc4f43a5be08795784c473
Autor:
E. Lasagna, S. Ceccobelli, I. Cardinali, F. Perini, U. Bhadra, K. Thangaraj, R.C. Dababani, N. Rai, F.M. Sarti, H. Lancioni, A.O. Ige
Publikováno v:
Poultry Science, Vol 99, Iss 6, Pp 2852-2860 (2020)
Poultry are the most widely distributed type of livestock in Nigeria. Indigenous chickens are extremely common throughout the country. Indeed, approximately 83 million chickens are raised in extensive systems and 60 million in semi-intensive systems.
Externí odkaz:
https://doaj.org/article/f4466c8b7db24b00bf6fa0da3dd70373
Autor:
M. L. Wang, W. Jurczak, M. Jerkeman, J. Trotman, P. L. Zinani, D. Belada, C. Boccomini, I. W. Flinn, P. Giri, A. Goy, P. A. Hamlin, O. Hermine, J.-Á. Hernández-Rivas, X. Hong, S. J. Kim, D. Lewis, Y. Mishima, M. Özcan, G. F. Perini, C. Pocock, Y. Song, S. E. Spurgeon, J. M. Storring, J. Walewski, J. Zhu, R. Qin, T. Henninger, S. Deshpande, A. Howes, S. Le Gouill, M. Dreyling
Publikováno v:
HemaSphere, Vol 6, Pp 110-111 (2022)
Externí odkaz:
https://doaj.org/article/376e7781201b418cb8dbbd3db9aea94e
Autor:
Neil J. Shah, Sneha D. Sura, Reshma Shinde, Junxin Shi, Puneet K. Singhal, Nicholas J. Robert, Nicholas J. Vogelzang, Rodolfo F. Perini, Robert J. Motzer
Publikováno v:
European Urology Open Science. 49:110-118
Autor:
R. Motzer, C. Porta, B. Alekseev, S. Y. Rha, T. K. Choueiri, M. J. Mendez-Vidal, S. H. Hong, A. Kapoor, J. C. Goh, M. Eto, L. Bennett, J. Wang, J. J. Pan, T. L. Saretsky, R. F. Perini, C. S. He, K. Mody, D. Cella
Publikováno v:
Cancer Urology. 18:39-57
Autor:
Michael L, Wang, Wojciech, Jurczak, Mats, Jerkeman, Judith, Trotman, Pier L, Zinzani, David, Belada, Carola, Boccomini, Ian W, Flinn, Pratyush, Giri, Andre, Goy, Paul A, Hamlin, Olivier, Hermine, José-Ángel, Hernández-Rivas, Xiaonan, Hong, Seok Jin, Kim, David, Lewis, Yuko, Mishima, Muhit, Özcan, Guilherme F, Perini, Christopher, Pocock, Yuqin, Song, Stephen E, Spurgeon, John M, Storring, Jan, Walewski, Jun, Zhu, Rui, Qin, Todd, Henninger, Sanjay, Deshpande, Angela, Howes, Steven, Le Gouill, Martin, Dreyling, Joseph C, Gardiner
Publikováno v:
New England Journal of Medicine. 386:2482-2494
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.We randoml
Autor:
Antoni Ribas, Toni K. Choueiri, Rodolfo F. Perini, Blanca Homet Moreno, Xinxin Shu, Seth Robey, Lokesh Jain, Marihella James, Shailender Bhatia, Deborah J. Wong, Nancy A. Dawson, Donald P. Lawrence, Wen-Jen Hwu, David F. McDermott, John A. Thompson, F. Stephen Hodi, Michael B. Atkins
Treatment-Related Adverse Events Occurring in {greater than or equal to}1 Patient Treated With Pembrolizumab plus Ipilimumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a5a64cf4ee8ebdd137cf92b274d8b1f
https://doi.org/10.1158/1078-0432.22469943
https://doi.org/10.1158/1078-0432.22469943
Autor:
Antoni Ribas, Toni K. Choueiri, Rodolfo F. Perini, Blanca Homet Moreno, Xinxin Shu, Seth Robey, Lokesh Jain, Marihella James, Shailender Bhatia, Deborah J. Wong, Nancy A. Dawson, Donald P. Lawrence, Wen-Jen Hwu, David F. McDermott, John A. Thompson, F. Stephen Hodi, Michael B. Atkins
Purpose: Pembrolizumab monotherapy, ipilimumab monotherapy, and pegylated interferon alfa-2b (PEG-IFN) monotherapy are active against melanoma and renal cell carcinoma (RCC). We explored the safety and preliminary antitumor activity of pembrolizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a51e52add57777cc2d463d414a0e017
https://doi.org/10.1158/1078-0432.c.6527397.v1
https://doi.org/10.1158/1078-0432.c.6527397.v1
Autor:
Robert Motzer, Saby George, Jaime R Merchan, Thomas E Hutson, Xun Song, Rodolfo F Perini, Ran Xie, Urmi Bapat, Javier Puente
Publikováno v:
The Oncologist.
BackgroundLenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma in the CLEAR study (NCT02811861). Here, we used CLEAR data to